Phase 4 N=64 Buffered Lidocaine in the Pediatric Dental Patient
Pediatric Dentistry
Primary: Patient Reported Pain Perception — 3.52; 3.48 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=110 Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
Kidney Calculi · Urologic Diseases · Benign Prostatic Hypertrophy
Primary: Same-day Discharge Rate — 50; 49 Participants
Phase 4 N=40 Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Chronic Sinusitis · Nasal Obstruction · Turbinate; Hypertrophy Mucous Membrane
Primary: Bleeding VAS - POD1 — 5.03; 4.82 score on a scale — p=0.8
Phase 4 N=22 Subantimicrobial Doxycycline in Acne
Acne Vulgaris · Pediatrics
Primary: Patient Perceptions of Their Acne Treatment — 8; 8; 7; 7 score on a scale — p=0.677
Phase 4 N=1,638 Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures
Surgical Site Infection · Unplanned Fracture-Related Reoperation · Open Appendicular Fracture
Primary: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI) — 13; 7 Participants
Phase 4 N=20 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
Diabetic Retinopathy · Macular Edema
Primary: Efficacy of Treatment Outcomes by Change in Visual Acuity From Baseline — 69.95; 74 letters
Phase 4 N=333 Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
Chronic Kidney Disease Requiring Chronic Dialysis · Hyperphosphatemia
Primary: Effect of Tenapanor to Achieve Target s-P Levels of Less Than or Equal to 5.5 mg/dL — 52; 58; 19 Participants
Phase 4 N=172 A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
Hyperphosphatemia · End Stage Renal Disease
Primary: Achieving Normal Serum Phosphorus Level — 36; 21 Participants — p=0.7439
Phase 4 N=105 Dapagliflozin at Discharge on Hospital Heart Failure Readmission
Heart Failure · Diabetes
Primary: Number of Participants With Hospital Admissions, Emergency Department Visits, Urgent Clinic Visits, and Death — 0; 3 Participants
Phase 4 N=249 A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
Urge Incontinence · Overactive Bladder (OAB)
Primary: Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group — -3.76 micturitions per 24 hours…
Phase 4 N=129 Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis
Plaque Psoriasis
Primary: The Number of Participants With Hypothalmic Pituitary Adrenal Axis Function Suppression as Measured by Cortisol Response Test — 21; 13; 2 Participants
Phase 4 N=60 Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants
Bradycardia · Arrhythmias
Primary: Incidence of Bradycardia — 0; 0 participants
Phase 4 N=70 Morphine Added to Ropivacaine for FICB for Postoperative Analgesia
Postoperative Pain
Primary: Duration of Analgesia — 541; 634 minutes
Phase 4 N=216 Dymista Allergen Chamber - Onset of Action Study
Seasonal Allergic Rhinitis
Primary: Change in Patient-assessed Instantaneous Total Nasal Symptom Score (TNSS) From Baseline Compared to Placebo — -1.37; -1.04 score on a scale — p=0.028
Phase 4 N=64 Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery
Chronic Pain
Primary: Morphine Equivalents Used During the First 48 Hours Post-Surgery — 180; 142.5 morphine milligram equivalent (MME)